Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:Takeda_Pharmaceutical_Company
|
| gptkbp:acquisition |
gptkb:Takeda_Pharmaceutical_Company
|
| gptkbp:ceo |
gptkb:Eduardo_Bravo
|
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:focus |
gptkb:drug
|
| gptkbp:founded |
gptkb:2000
|
| gptkbp:headquarters |
gptkb:Leuven,_Belgium
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ti Genix
|
| gptkbp:industry |
gptkb:drug
|
| gptkbp:market |
gptkb:Europe
|
| gptkbp:partnership |
Universities and research institutions
|
| gptkbp:products |
gptkb:Chondro_Celect
gptkb:Cx601 |
| gptkbp:regulatory_compliance |
gptkb:European_Medicines_Agency
|
| gptkbp:research_areas |
regenerative medicine
|
| gptkbp:symbol |
TIG
|
| gptkbp:technology |
gptkb:smartphone
|
| gptkbp:type |
gptkb:Company
|
| gptkbp:website |
www.tigenix.com
|